Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors.
When skeletons of Win compounds were used as templates, computer-assisted drug design led to the identification of a novel series of imidazolidinone derivatives with significant antiviral activity against enterovirus 71 (EV 71), the infection of which had resulted in about 80 fatalities during the 1998 epidemic outbreak in Taiwan. In addition to inhibiting all the genotypes (A, B, and C) of EV 71 in the submicromolar to low micromolar range, compounds 1 and 8 were extensively evaluated against a variety of viruses, showing potent activity against coxsackievirus A9 (IC(50) = 0.47-0.55 microM) and coxsackievirus A24 (IC(50) = 0.47-0.55 microM) as well as moderate activity against enterovirus 68 (IC(50) = 2.13 microM) and echovirus 9 (IC(50) = 2.6 microM). Our SAR studies revealed that imidazolidinone analogues with an aryl substituent at the para position of the phenoxyl ring, such as compounds 20, 21, 27, 57, 58, and 61, in general exhibited the highest activity against EV 71. Among them, compound 20 and its corresponding hydrochloride salt 57, in terms of potency and selectivity index, appear to be the most promising candidates in this series for further development of anti-EV-71 agents. Preliminary results of the study on the mode of action by a time-course experiment suggest that test compounds 1 and 8 can effectively inhibit the virus replication at the early stages, referring to virus attachment or uncoating. This indicates that the surface protein may be the target for this type of compounds.
Shia
Kak-Shan
KS
Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taipei 11529, Taiwan, R.O.C. srshih@mail.cgu.edu.tw
Li
Wen-Tai
WT
Chang
Chung-Ming
CM
Hsu
Ming-Chu
MC
Chern
Jyh-Haur
JH
Leong
Max K
MK
Tseng
Sung-Nien
SN
Lee
Chung-Chi
CC
Lee
Yen-Chun
YC
Chen
Shu-Jen
SJ
Peng
Kuan-Chang
KC
Tseng
Huan-Yi
HY
Chang
Yi-Ling
YL
Tai
Chia-Liang
CL
Shih
Shin-Ru
SR
D000818:Animals; D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D002460:Cell Line; D002522:Chlorocebus aethiops; D004770:Enterovirus / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D009500:Neutralization Tests; D010069:Oxadiazoles / Q000737:chemistry; D010080:Oxazoles; D011725:Pyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D010948:Viral Plaque Assay
C453478:1-(5-(biphenyl-4-yloxy)pentyl)-3-pyridin-4-ylimidazolidin-2-one; D000998:Antiviral Agents; D007093:Imidazoles; D010069:Oxadiazoles; D010080:Oxazoles; D011725:Pyridines; C115201:pleconaril